Skip to main content
money pills teaser

Surescripts acquires ActiveRADAR

ActiveRADAR offers evidence-based, formulary-specific and medically accepted use-specific therapeutic alternatives.

Surescripts, a health information network, has acquired ActiveRADAR, a clinical intelligence company that identifies therapeutic alternatives for prescriptions.

“We are always looking for ways to broaden our impact on patients and the people who care for them,” said Frank Harvey, CEO of Surescripts. “Our acquisition of ActiveRADAR underscores our commitment to optimizing our network solutions with even more comprehensive clinical and cost data available at the point of prescribing. Together, we can make it simpler and faster to get patients started on the best medication for them.”

ActiveRADAR (formerly known as RxTE Health) offers evidence-based, formulary-specific and medically accepted use-specific therapeutic alternatives, along with corresponding dosage strengths, quantities and plan-specific patient and health plan costs. ActiveRADAR’s Clinical Catalogue covers more than 165 therapeutic categories, including more than 30 specialty drug categories and more than 33,000 drug pairs, as well as both clinical and economic value on medication alternatives, and has been shown to reduce costs for employers and employees by 15 to 20%, Surescripts said.

[Read more: Cutting edge specialty offerings]

“We are very pleased to have reached this agreement which will allow ActiveRADAR to have a direct impact on improving medication adherence as well as patient and provider engagement,” said Dave Teckman, former CEO of ActiveRADAR. “Our analytical processes target and prioritize savings opportunities to minimize member disruption and maximize savings, which ultimately improves the patient experience and takes waste and costs out of the system.”

“Providing faster access to insights and optimizing the value delivered by our data are two of our biggest priorities, so we’re thrilled to have the ActiveRADAR team joining Surescripts,” said Lynne Nowak, chief data and analytics officer of Surescripts. “With access to their extensive catalog of therapeutic alternatives data, we can reduce drug spend and help provide more alternatives when deploying prescription pricing information to providers.”

[Read more: Surescripts reports healthcare interoperability reached record levels in 2022]

This ad will auto-close in 10 seconds